New mRNA vaccine trial hopes to stop pancreatic cancer return

NCT ID NCT06496373

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a personalized mRNA vaccine (XP-004) combined with a PD-1 inhibitor in 20 patients who cannot tolerate chemotherapy after pancreatic cancer surgery. The goal is to see if the treatment is safe and can train the immune system to fight remaining cancer cells, potentially delaying or preventing cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INTOLERANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INTOLERANT PANCREATIC CANCER RESECTABLE

Contacts and locations

Locations

Ruijin Hospital Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.